Croda International H1 2026 Results: Beauty Growth Lifts Profit and Margin

Croda International PLC has delivered a solid first half of 2026, with stronger Consumer Care demand helping profits grow faster than sales.

Reported sales increased by 2.9% to £880.5 million, while organic sales growth was 4.6%. Organic growth strips out currency movements and the first-year effect of acquisitions or disposals, giving investors a clearer view of underlying trading.

Adjusted operating profit rose by 6.1% on a reported basis to £155.8 million, or 6.7% organically. This lifted the adjusted operating margin from 17.2% to 17.7%.

The full-year outlook remains unchanged despite geopolitical and macroeconomic uncertainty. You can read the original company announcement for the complete financial statements.

Croda's key first-half figures

Metric	H1 2026	H1 2025	Change
Sales	£880.5m	£855.8m	2.9%
Organic sales growth	4.6%	Not disclosed	Not applicable
Adjusted EBITDA	£207.9m	£198.5m	5.5% organic
Adjusted operating profit	£155.8m	£146.9m	6.7% organic
Adjusted operating margin	17.7%	17.2%	0.5 percentage points
IFRS operating profit	£115.5m	£94.4m	22.4%
Adjusted basic EPS	78.6p	72.2p	8.9%
Free cash flow	£38.3m	£28.0m restated	36.8%
Net debt	£577.9m	£580.1m	0.4% lower
Interim dividend	48.0p	48.0p	Unchanged

The headline attraction is the combination of underlying sales growth, a higher margin and improved free cash flow. That suggests Croda's transformation programme is beginning to support the financial performance rather than merely generating restructuring costs.

Consumer Care is doing the heavy lifting

Consumer Care was the clear standout. Sales increased organically by 8.3% to £523.7 million, with growth across each business unit:

• Beauty Actives: 19%
• Beauty Care: 4%
• Home Care: 9%
• Fragrances & Flavours: 8%

Adjusted operating profit in the division increased organically by 14.3% to £98.1 million. Its adjusted operating margin rose from 17.4% to 18.7%, helped by favourable sales mix and transformation savings.

Beauty Actives was particularly strong, supported by customer demand for innovation and premium products. Croda is also targeting more affordable beauty categories, where management says it is growing market share despite pressure on lower-income consumers.

There was a notable acceleration during the second quarter. Group organic sales growth improved from 0.8% in Q1 to 8.8% in Q2, while Consumer Care growth accelerated from 3.6% to 13.5%.

That improvement builds on the mixed segment picture highlighted in Croda's first-quarter 2026 sales update. However, Q2 also benefited from a less demanding prior-year comparison, so investors should not assume that the quarterly growth rate will automatically continue.

Life Sciences remains the main soft spot

Life Sciences sales were broadly flat organically at £257.3 million. Adjusted operating profit fell by 2.4% organically to £53.7 million, with the margin declining from 21.5% to 20.9%.

Performance within the division was mixed:

• Pharma sales increased by 1%
• Seed Enhancement sales increased by 4%
• Crop Protection sales fell by 2%

Croda is rebalancing Pharma towards its Ingredients portfolio, which accounts for more than 70% of Pharma sales. Ingredients grew by 7%, suggesting this shift is gaining some traction.

However, Pharma Solutions sales fell by 17%. This is a smaller and more project-driven business, and Croda attributed the decline to project phasing. Management expects project revenue to improve in the second half, supported by the order book, but delivery remains important.

Industrial Specialties was also weaker. Organic sales fell by 1.9% to £99.5 million, while adjusted operating profit declined to £4.0 million from £5.1 million.

Transformation savings are supporting margins

Croda delivered £18 million of incremental transformation savings during the half. This was in addition to £10 million included in the first-half 2025 comparison and £18 million delivered in the second half of 2025.

The company remains on track to deliver approximately £100 million of annualised efficiency benefits and around £50 million of working capital improvements for full-year 2028.

These savings are important because adjusted operating profit grew faster than sales. Croda expects a further sequential margin increase in the second half, supported by growth and additional efficiencies.

There is still a cost attached. Restructuring and transformation charges increased to £17.5 million from £7.4 million. Total adjustments were £40.3 million, including £5.1 million of impairment charges and £17.7 million of acquired intangible asset amortisation.

Cash flow improved, but working capital absorbed cash

Free cash flow increased by 36.8% to £38.3 million, helped by lower capital expenditure. Net capital expenditure fell to £42.8 million from £59.5 million.

However, working capital produced a £67.8 million outflow, compared with £60.7 million a year earlier. Croda said this supported stronger growth that accelerated in Q2 and affected the period-end position.

Net debt was broadly stable at £577.9 million, while leverage improved from 1.5 times to 1.4 times adjusted EBITDA. This remains within Croda's target range of one to two times.

The interim dividend was held at 48.0p per share. Management is seeking to restore earnings cover and reduce the payout ratio, meaning profit growth is currently taking priority over dividend growth.

What investors should watch next

Croda continues to expect full-year organic sales growth within its 3% to 6% range, alongside another increase in the adjusted operating margin. Its expectations for full-year adjusted operating profit are unchanged.

Key points to monitor include:

1. Whether Consumer Care can maintain its improved momentum.
2. Whether delayed Pharma Solutions projects convert into second-half sales.
3. Whether further transformation savings produce another margin increase.
4. Whether working capital performance improves as growth settles.
5. The currency headwind, which could reduce reported full-year operating profit by approximately £4 million if second-half exchange rates match June closing levels.

There are also non-financial concerns. Croda's total recordable injury rate worsened to 0.78 from 0.45, against a target of 0.3 by the end of 2026. Management described this as a disappointing step backwards and said improvement work is under way.

A stronger half, with Pharma delivery still required

Croda's first-half results show meaningful progress. Consumer Care is growing strongly, innovation-led products are outperforming total sales, margins are moving higher and cash flow has improved.

The less convincing parts are Life Sciences, the working capital outflow and the still-significant cost of transformation. The unchanged outlook is reassuring, but it also places weight on a better second-half contribution from Pharma Solutions and continued delivery of efficiency savings.

Croda's next scheduled update will cover third-quarter sales performance on 5 November 2026.